Results 141 to 150 of about 111,455 (252)

Bi‐ and Mono‐Allelic RFC1 Expansion in a North American Cohort With Idiopathic Axonal Neuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective RFC1 biallelic repeat expansion is increasingly recognized as a cause of chronic idiopathic axonal polyneuropathy (CIAP), but it remains challenging to know who to test. This study aims to determine the prevalence of biallelic and monoallelic RFC1 expansions and their corresponding neuropathy phenotypes in CIAP patients and identify ...
Amro M. Stino   +25 more
wiley   +1 more source

Methods and evidence in economic evaluations of modern radiotherapy: a systematic mapping review protocol. [PDF]

open access: yesBMJ Open
Veneruso F   +8 more
europepmc   +1 more source

Database for Cost of Delivering Vaccines Using Different Delivery Strategies in High Coverage Areas in Indonesia

open access: yes
The Immunization Costing Action Network (ICAN) was a three-year project, supported by the Bill & Melinda Gates Foundation and facilitated by ThinkWell and JSI, which included the implementation of costing studies in Indonesia, Tanzania, and Vietnam ...
Immunization Costing Action Network
core   +1 more source

Blood RNA Biomarker Signatures for Early Diagnosis and Prognosis in Ischemic and Hemorrhagic Stroke: The IBIS‐CT1 Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the expression of nine blood RNA biomarkers in a clinical trial based on genes previously identified in an experimental monkey model of stroke for diagnosis feasibility and prognostication. Methods IBIS‐CT1 was a prospective longitudinal study enrolling patients with ischemic stroke (IS) or intracerebral hemorrhage (ICH ...
Salomé Retailleau   +11 more
wiley   +1 more source

Database for Costs of Different Vaccine Delivery Strategies to Reach Children Up to 18 Months in Rural and Urban Areas in Tanzania

open access: yes
The Immunization Costing Action Network (ICAN) was a three-year project, supported by the Bill & Melinda Gates Foundation and facilitated by ThinkWell and JSI, which included the implementation of costing studies in Indonesia, Tanzania, and Vietnam ...
Immunization Costing Action Network
core   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch   +5 more
wiley   +1 more source

Supply, demand and use of economic evidence in vaccine policymaking in Africa: A scoping review. [PDF]

open access: yesPLOS Glob Public Health
Mazuba E   +8 more
europepmc   +1 more source

The value of more accurate customer profitability reports: Does cost complexity matter?. [PDF]

open access: yes
This paper reports experimental evidence on the potential benefits of reporting different levels of customer-related information in a pricing decision context.
Cardinaels, Eddy   +3 more
core  

Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Novel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration. Objectives This study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
Bing Wu   +7 more
wiley   +1 more source

Manufacturing cost analysis and exploratory economic evaluation of natural killer cell immunotherapy for paediatric solid tumors. [PDF]

open access: yesClin Transl Immunology
Wahid ST   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy